Verstovsek S et al. -In the current study, the long-term survival benefit of ruxolitinib was shown in patients with intermediate-2 or high-risk myelofibrosis (MF).

Methods

• The current study was an exploratory analysis of 5-year data pooled from the phase 3 COMFORT-I and -II trials.
• Overall survival was evaluated using pooled intent-to-treat data from patients randomized to ruxolitinib or the control groups.

Results

• 528 patients were included in the analysis.
• The risk of death was reduced by 30% among patients randomized to ruxolitinib compared with patients in the control group (median OS, 5.3 vs. 3.8 years, respectively; HR, 0.70).
• The OS advantage was more pronounced for patients who were originally randomized to ruxolitinib compared with patients who crossed over from control to ruxolitinib (median OS, 5.3 vs. 2.3 years; HR, 0.35).
• OS censoring patients at the time of crossover also demonstrated that ruxolitinib prolonged OS compared with control (median OS, 5.3 vs. 2.4 years; HR, 0.53).
• The survival benefit with ruxolitinib was observed irrespective of baseline anemia status or transfusion requirements at week 24.